Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
The Lancet - Early Online Publication, 06/25/09
Priotto G et al. - The efficacy of NECT is non-inferior to that of eflornithine monotherapy. Since this combination treatment also presents safety advantages, is easier to administer (ie, infusion every 12 h for 7 days vs every 6 h for 14 days), and potentially protective against the emergence of resistant parasites, it is suitable for first-line use in HAT control programmes.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Drugs for preventing malaria in travellers
Cochrane Reviews, 10/22/09
Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, 10/20/09
Empirical Antimicrobial Therapy for Bloodstream Infection Due to Methicillin-Resistant Staphylococcus aureus: No Better than a Coin Toss
Infection Control and Hospital Epidemiology, 10/14/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists
Clinical Therapeutics, 10/15/09
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials
Current Medical Research and Opinion, 10/27/09
Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
Digestion, 10/15/09
Sponsor
Article Search
Sponsor


See Latest Articles


